119 related articles for article (PubMed ID: 33767957)
1. Rituximab for autoimmune retinopathy: Results of a Phase I/II clinical trial.
Armbrust KR; Fox AR; Jeffrey BG; Sherry P; Sen HN
Taiwan J Ophthalmol; 2021; 11(1):64-70. PubMed ID: 33767957
[TBL] [Abstract][Full Text] [Related]
2. Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy.
Uludag G; Onal S; Arf S; Sayman Muslubas I; Selcukbiricik F; Koc Akbay A; Molinas Mandel N
Am J Ophthalmol Case Rep; 2016 Jul; 2():4-7. PubMed ID: 29503888
[TBL] [Abstract][Full Text] [Related]
3. Rituximab Monotherapy versus Rituximab and Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy.
Maleki A; Colombo A; Look-Why S; Peter Y Chang BA; Anesi SD; Anesi SD
J Ophthalmic Vis Res; 2022; 17(4):515-528. PubMed ID: 36620716
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy.
Boudreault K; Justus S; Sengillo JD; Schuerch K; Lee W; Cabral T; Tsang SH
Orphanet J Rare Dis; 2017 Jul; 12(1):129. PubMed ID: 28709429
[TBL] [Abstract][Full Text] [Related]
5. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial.
Suhler EB; Lim LL; Beardsley RM; Giles TR; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Smith JR; Rosenbaum JT
Ophthalmology; 2014 Oct; 121(10):1885-91. PubMed ID: 24953794
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
[TBL] [Abstract][Full Text] [Related]
7. Management of autoimmune retinopathies with immunosuppression.
Ferreyra HA; Jayasundera T; Khan NW; He S; Lu Y; Heckenlively JR
Arch Ophthalmol; 2009 Apr; 127(4):390-7. PubMed ID: 19365013
[TBL] [Abstract][Full Text] [Related]
8. Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy.
Maleki A; Lamba N; Ma L; Lee S; Schmidt A; Foster CS
Clin Ophthalmol; 2017; 11():377-385. PubMed ID: 28255228
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in Autoimmune Retinopathy Patients Treated With Rituximab.
Davoudi S; Ebrahimiadib N; Yasa C; Sevgi DD; Roohipoor R; Papavasilieou E; Comander J; Sobrin L
Am J Ophthalmol; 2017 Aug; 180():124-132. PubMed ID: 28483493
[TBL] [Abstract][Full Text] [Related]
11. Non-paraneoplastic autoimmune retinopathy that developed in fellow eye 10 years after onset in first eye: a case report.
Miura G; Baba T; Iwase T; Ohde H; Kanda A; Saito W; Ishida S; Yamamoto S
BMC Ophthalmol; 2020 Apr; 20(1):132. PubMed ID: 32252709
[TBL] [Abstract][Full Text] [Related]
12. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.
Fluge Ø; Risa K; Lunde S; Alme K; Rekeland IG; Sapkota D; Kristoffersen EK; Sørland K; Bruland O; Dahl O; Mella O
PLoS One; 2015; 10(7):e0129898. PubMed ID: 26132314
[TBL] [Abstract][Full Text] [Related]
13. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Joly P; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Vermeulin T; Benichou J; Musette P;
Lancet; 2017 May; 389(10083):2031-2040. PubMed ID: 28342637
[TBL] [Abstract][Full Text] [Related]
14. Rituximab treatment for nonparaneoplastic autoimmune retinopathy.
Fox A; Jeffrey B; Hasni S; Nussenblatt R; Sen HN
Can J Ophthalmol; 2015 Dec; 50(6):e101-4. PubMed ID: 26651312
[No Abstract] [Full Text] [Related]
15. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
[TBL] [Abstract][Full Text] [Related]
17. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Immunoglobulin for Management of Non-paraneoplastic Autoimmune Retinopathy.
Fekri S; Soheilian M; Rahimi-Ardabili B
J Ophthalmic Vis Res; 2020; 15(2):246-251. PubMed ID: 32308960
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
